8-K: Biote Corp. Reports Profitable Growth in Third Quarter 2024, Driven by Vertical Integration and New Software Launch

Biote Corp. announced its third quarter 2024 financial results, highlighting revenue growth, improved gross profit margins, and the launch of new clinical decision support software.

Summary

• Biote Corp. reported a revenue of $51.4 million for the third quarter of 2024, a 12.8% increase compared to the prior-year period.
• Procedure revenue reached $37.9 million, showing a 7.1% growth, while dietary supplement revenue grew by 21.7%.
• The company's gross profit margin improved to 70.5%, up from 68.9% in the same quarter of the previous year, primarily due to vertical integration of manufacturing.
• Net income for the quarter was $12.7 million, or $0.33 per diluted share, compared to $19.6 million, or $0.24 per diluted share, in the third quarter of 2023, with the change primarily due to a change in the fair value of earnout liabilities.
• Adjusted EBITDA was $16.2 million, with an Adjusted EBITDA margin of 31.5%, reflecting a 15.4% increase compared to the third quarter of 2023.
• The company experienced a temporary disruption in procedure volume due to the introduction of new clinical decision support software and hurricane-related clinic closures.
• Biote has adjusted its 2024 financial guidance to $197-$201 million in revenue and $58-$61 million in Adjusted EBITDA.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with strong revenue growth and improved margins offset by a decrease in net income, temporary disruptions, and lowered guidance. The launch of new software is a positive, but the overall sentiment is cautiously optimistic.

Positives

• Revenue increased by 12.8% year-over-year, indicating strong growth.
• Gross profit margin improved to 70.5%, driven by vertical integration and cost management.
• Adjusted EBITDA increased by 15.4% year-over-year, demonstrating improved profitability.
• The launch of new clinical decision support software is expected to strengthen the company's competitive position.
• Dietary supplement revenue grew by 21.7%, showing a strong return to growth in this segment.
• Operating income increased due to higher sales, improved gross profit margin, and controlled operating expenses.

Negatives

• Net income decreased compared to the same quarter last year, primarily due to a change in the fair value of earnout liabilities.
• The introduction of new clinical decision support software caused a temporary disruption in procedure volume.
• Hurricane-related clinic closures also negatively impacted procedure volume.
• The company has lowered its full-year 2024 revenue and Adjusted EBITDA guidance.

Risks

• The company faces risks related to the market acceptance of its dietary supplements.
• Reliance on third parties for manufacturing bio-identical hormones poses a risk.
• Regulatory, economic, environmental, and competitive conditions could impact the company's performance.
• The company's ability to maintain and increase the use of the Biote Method by practitioners is crucial.
• The company operates in a highly competitive industry.
• The company's limited operating history presents a risk.
• The company is subject to heavy regulatory oversight.
• The company's performance could be impacted by economic, business, and competitive factors, including natural disasters.
• Future exchange and interest rates could pose a risk.

Future Outlook

Biote expects some residual impact on procedure revenue in the fourth quarter of 2024 due to the software implementation and hurricane-related closures, but anticipates procedure revenue growth will reaccelerate in 2025. The company has adjusted its 2024 financial guidance to $197-$201 million in revenue and $58-$61 million in Adjusted EBITDA.

Management Comments

• Biote's CEO, Terry Weber, stated that the company's third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to growth in our dietary supplements business.
• Ms. Weber noted that the company achieved a solid improvement in gross profit margin, primarily reflecting cost savings from the vertical integration of manufacturing.
• Ms. Weber mentioned that the company introduced several major enhancements to the Biote Method in September 2024, expanding its evidence-based approach to hormone optimization and therapeutic wellness.
• Ms. Weber commented that the company is confident that its advanced clinical decision support software represents a key competitive differentiator for Biote.
• Ms. Weber stated that the company continues to make solid progress in driving growth in its top-tier clinics and further expanding its practitioner network.

Industry Context

Biote's focus on personalized hormone optimization and therapeutic wellness aligns with the growing trend of preventive healthcare and personalized medicine. The launch of proprietary clinical decision support software indicates a move towards leveraging technology to enhance patient care and gain a competitive edge in the market.

Comparison to Industry Standards

• Biote's gross profit margin of 70.5% is strong compared to other healthcare and wellness companies, indicating efficient cost management and vertical integration benefits.
• The company's Adjusted EBITDA margin of 31.5% is also competitive, suggesting good operational efficiency.
• Companies like Thorne HealthTech and LifeMD, which also operate in the wellness and telehealth space, have similar revenue growth targets, but Biote's focus on hormone optimization provides a unique market position.
• The launch of clinical decision support software is a strategic move similar to other healthcare companies that are investing in technology to improve patient outcomes and streamline operations.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and lowered guidance.
• Practitioners will benefit from the new clinical decision support software.
• Patients are expected to receive enhanced, personalized treatments.
• Employees may be impacted by the company's growth and strategic initiatives.

Next Steps

• Biote will continue to support practitioners with additional workflow guidance and software training.
• The company expects procedure revenue growth to reaccelerate in 2025.
• Biote management will host a conference call to review the results and provide a business update.

Key Dates

Keywords

Biote, Hormone Optimization, Preventive Healthcare, Financial Results, Adjusted EBITDA, Gross Profit Margin, Clinical Decision Support Software, Dietary Supplements, Procedure Revenue, Vertical Integration